The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1

Cardiovascular Drugs and Therapy

Volumn 13, Issue 3, 1999, Pages 217-222

  Szwed, Hanna ^a   Sadowski, Zygmunt ^a   Pachocki, Robert ^b   Domzał Bocheńska, Małgorzata ^b   Szymczak, Krzysztof ^c   Szydłowski, Zbigniew ^d   Paradowski, Andrzej ^e   Gajos, Grzegorz ^e   Kałuza, Grzegorz ^e   Kulon, Irena ^f   Wa̧tor Brzezińska, Anna ^c   Elikowski, Waldemar ^g   Kuźniak, Maria ^h  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b Servier Polska   (Poland)

^c Voivodeship Cardiological Center   (Poland)

^d PCK   (Poland)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f G Narutowicza   (Poland)

^g J Strusia Hospital   (Poland)

^h District Hospital   (Poland)

Author keywords

Coronary heart disease; Diabetes mellitus; Ischemia; Tolerability; Trimetazidine

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRATE; TRIMETAZIDINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; EXERCISE TOLERANCE; FEMALE; HEART MITOCHONDRION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREADMILL EXERCISE;

DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 0033036313     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007744109064     Document Type: Article

References (31)

1. 1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-444.
2. 2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
3. 3. Henry P, Makowski S, Richard P, et al. Increased incidence of moderate stenosis among patients with diabetes: Substrate for myocardial infarction? Am Heart J 1997;134; 1037-1043.
4. 4. Ambrose JA, Tonnenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
5. 5. Little WC Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-1166.
6. 6. Nobuyoshi M, Tanaka M, Nosaka H, et al. Progression of coronary atherosclerosis: Is coronary spasm related to progression? J Am Coll Cardiol 1991;18:904-910.
7. 7. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69:729-732.
8. 8. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction; contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 1989;14:49-57.
9. 9. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovascular Res 1997;34:25-33.
10. 10. Barrett EJ, Schwartz RG, Francis CK, Zaret BL. Regulation by insulin of myocardial glucose and fatty acid metabolism in the conscious dog. J Clin Invest 1984;74:1073-1079.
11. 11. Gamble J, Lopaschuk GD. Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats. Biochem Biophys Acta 1994;1225:191-199.
12. 12. Lopaschuk GD. Abnormal mechanical function in diabetes: Relationship to altered myocardial carbohydrate/lipid metabolism. Cor Artery Dis 1996;7:116-123.
13. 13. Oliver MF, Kurien VA, Greenwood TW. Relation between serum-free-fatty-acids and arrhythmias and death after acute myocardial infarction. Lancet 1968;1:710-715.
14. 14. Boddeke E, Hugtenburg J, Jap W, Heynis J, van Zwieten P. New anti-ischaemic drugs: Cytoprotective action with no primary haemodynamic effects. Trends Pharmacol Sci 1989;10:379-400.
15. 15. Pornin M, Harpey C, Allal J, Sellier P, Ourbak P. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: A placebo-controlled study. Clin Trials Meta-Analysis 1994;29:49-56.
16. 16. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart (abstr). J Mol Cell Cardiol 1998; 30:A112.
17. 17. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: Beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993;21:128-135.
18. 18. Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated rat heart by trimetazidine: Effects on the energy state and mitochondrial function. Am J Cardiol 1995;76:45B-49B.
19. 19. Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increasesphospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997;175:153-162.
20. 20. Dalla-Volta S, Maraglino G, Della-Valentina P, Vienna P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther 1990;4(Suppl.4):853-859.
21. 21. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patientswith stable angina. Br J Clin Pharmacol 1994;37:279-288.
22. 22. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997;78:353-357.
23. 23. Michaelides AP, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propanolol compared with isosorbide dinitrate-propanolol in patients with stable angina. Clin Drug Invest 1997;13:8-14.
24. 24. Szwed H, Pachocki R, Domźal-Bocheńska M, et al. Skutecznośé i tolerancja trimetazydyny jako leku wieńcowego u chorych z wysiłkowa̧ dusznica̧ bolesna̧ w skojarzeniu z jednym lekiem przeciwdławicowym. Elektrofizjologia i Stymulacja Serca 1997;4:237-247.
25. 25. Sinha SK. Coronary angiography and coronary artery bypass grafts in diabetics. Diab Res Clin Pract 1996;30 (Suppl.): S89-S92.
26. 26. Stein B, Weintraub WS, Gebhart S, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91: 979-989.
27. 27. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.
28. 28. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998;31:10-19.
29. 29. Recommendations of the Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997;18:394-413.
30. 30. Desideri A. An overview of trimetazidine: Clinical studies in coronary heart disease. Res Clin Forums 1995;17:43-51.
31. 31. Reynolds JEF, ed. Martindale the Extrapharmacopoeia. London: Royal Pharmaceutical Press, 1996:830-831.